Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations

被引:116
作者
Fassas, ABT
Muwalla, F
Berryman, T
Benramdane, R
Joseph, L
Anaissie, E
Sethi, R
Desikan, R
Siegel, D
Badros, A
Toor, A
Zangari, M
Morris, C
Angtuaco, E
Mathew, S
Wilson, C
Hough, A
Harik, S
Barlogie, B
Tricot, G
机构
[1] Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[3] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA
[4] Univ Arkansas Med Sci, Dept Neurol, Little Rock, AR 72205 USA
关键词
multiple myeloma; central nervous system; high-risk features; allogeneic stem cell transplant;
D O I
10.1046/j.1365-2141.2002.03401.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Involvement of the central nervous system (CNS) by multiple myeloma, as defined by the detection of malignant plasma cells in the cerebrospinal fluid in the presence of suggestive symptoms, is considered extremely rare. We report on the characteristics of 18 such patients diagnosed and treated at the University of Arkansas over the last 10 years for an overall incidence of approximately 1%. Their evaluation revealed association of CNS involvement with unfavourable cytogenetic abnormalities (especially translocations and deletion of the chromosome 13), high tumour mass, plasmablastic morphology, additional extramedullary myeloma manifestations and circulating plasma cells. The presence of these features should alert clinicians to the possibility of CNS involvement. The outcome of these patients was extremely poor despite the use of aggressive local and systemic treatment including autologous stem cell transplants. Given this universally poor prognosis, the application of allogeneic transplants should be studied in this clinical setting.
引用
收藏
页码:103 / 108
页数:6
相关论文
共 15 条
  • [1] High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
    Badros, A
    Barlogie, B
    Morris, C
    Desikan, R
    Martin, SR
    Munshi, N
    Zangari, M
    Toor, A
    Cottler-Fox, M
    Fassas, A
    Aniassie, E
    Schichman, S
    Tricot, G
    [J]. BLOOD, 2001, 97 (09) : 2574 - 2579
  • [2] Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
    Barlogie, B
    Jagannath, S
    Vesole, DH
    Naucke, S
    Cheson, B
    Mattox, S
    Bracy, D
    Salmon, S
    Jacobson, J
    Crowley, J
    Tricot, G
    [J]. BLOOD, 1997, 89 (03) : 789 - 793
  • [3] Total therapy with tandem transplants for newly diagnosed multiple myeloma
    Barlogie, B
    Jagannath, S
    Desikan, KR
    Mattox, S
    Vesole, D
    Siegel, D
    Tricot, G
    Munshi, N
    Fassas, A
    Singhal, S
    Mehta, J
    Anaissie, E
    Dhodapkar, D
    Naucke, S
    Cromer, J
    Sawyer, J
    Epstein, J
    Spoon, D
    Ayers, D
    Cheson, B
    Crowley, J
    [J]. BLOOD, 1999, 93 (01) : 55 - 65
  • [4] INCIDENCE, PROGNOSTIC-SIGNIFICANCE AND THERAPEUTIC MODALITIES OF CENTRAL NERVOUS-SYSTEM INVOLVEMENT IN MULTIPLE-MYELOMA
    BRENNER, B
    CARTER, A
    TATARSKY, I
    GRUSZKIEWICZ, J
    PEYSER, E
    [J]. ACTA HAEMATOLOGICA, 1982, 68 (02) : 77 - 83
  • [5] HIGH SERUM LACTATE-DEHYDROGENASE LEVEL AS A MARKER FOR DRUG-RESISTANCE AND SHORT SURVIVAL IN MULTIPLE-MYELOMA
    DIMOPOULOS, MA
    BARLOGIE, B
    SMITH, TL
    ALEXANIAN, R
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (12) : 931 - 935
  • [6] Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group
    Greipp, PR
    Leong, T
    Bennett, JM
    Gaillard, JP
    Klein, B
    Stewart, JA
    Oken, MM
    Kay, NE
    Van Ness, B
    Kyle, RA
    [J]. BLOOD, 1998, 91 (07) : 2501 - 2507
  • [7] Kornberg A, 2000, BLOOD, V96, p347B
  • [8] LEIFER D, 1992, CANCER-AM CANCER SOC, V70, P1899, DOI 10.1002/1097-0142(19921001)70:7<1899::AID-CNCR2820700716>3.0.CO
  • [9] 2-3
  • [10] Petersen SL, 1999, AM J HEMATOL, V62, P228, DOI 10.1002/(SICI)1096-8652(199912)62:4<228::AID-AJH5>3.0.CO